The present disclosure relates to implantable intraocular lenses.
Implantation of artificial lenses into the human eye has been a standard technique for many years, both to replace the natural crystalline lens (aphakic eye) and to supplement and correct refractive errors of the natural lens (phakic eye). However, accommodation provided by such replacement lenses is minimal or non-existent.
The crystalline lens is a transparent structure that focuses light in the human eye. Opacification of the lens known as cataract formation is a common cause of poor vision in the elderly, and can be corrected surgically.
Modern cataract surgery is performed by manual extracapsular cataract extraction, or by phacoemulsification. In both operations an opening is made in the anterior capsule to allow removal of the lens. The capsular bag remnant, however, is left in situ to provide support for an intraocular lens implant which is inserted following removal of the cataract, to replace the focusing power of the natural crystalline lens.
It is known to provide an intraocular lens implant which typically comprises a central focusing element, known as an optic, and peripheral support structure, known as a haptic. The optic and the haptic of the intraocular lens may be manufactured from transparent rigid plastics material such as polymethyl methacrylate, or from flexible plastics material such as silicone or hydrogel. Intraocular lens implants manufactured from flexible material are typically preferable to those made of rigid material because the lens may be folded to allow insertion through a small incision in the sclera or outercoat of the eye and is then required to unfold to its original dimension.
The optic and haptic of the intraocular lens may be manufactured from the same material as a single piece unit or the haptic may be attached to the optic by a variety of mechanisms. There may be one or a plurality of haptics attached to the optic, although the most common configuration includes an optic with two outwardly extending haptics. The purpose of the haptic or haptics is to provide optimal centration of the optic as well as a means of fixation of the implant within the eye (e.g. within a capsular bag remnant of the original lens following cataract or lens extraction). It is preferable that the haptics conform to the periphery of the capsular bag to provide a larger surface area of contact between the intraocular lens implant and the capsular bag and to ensure centration of the optic.
It is also possible to implant a lens in front of the anterior capsule behind the iris with the haptics resting in the region between the root of the iris and cilairy processes, known as the ciliary sulcus.
Intraocular lenses may also be inserted in phakic eyes to correct refractive errors, such as myopia or hyperopia, in front of the crystalline lens behind the iris with the haptic providing support in the cilairy sulcus. Furthermore, as an alternative site of implantation in phakic eyes, intraocular lenses may be inserted in front of the iris in the anterior chamber with the haptics resting in the angle of the anterior chamber.
An example of a conventional intraocular lens 100 in accordance with the prior art shown in
Intraocular lenses differ with respect to their accommodation capability, and their placement in the eye. Accommodation is the ability of an intraocular lens to accommodate, which is to focus the eye for near and distant vision. Natural accommodation in a normal human eye involves shaping of the natural crystalline lens by automatic contraction and relaxation of the ciliary muscle of the eye by the brain to focus the eye at different distances. Ciliary muscle relaxation shapes the natural lens for distant vision. Ciliary muscle contraction shapes the natural lens for near vision.
Most non-accommodating implanted lenses have single focus optics which focus the eye at a certain fixed distance only and require the wearing of eye glasses to change the focus. Other non-accommodating lenses have multifocal optics which image both near and distant objects on the retina of the eye and provide both near vision and distant vision sight without eyeglasses. Multifocal intraocular lenses, however, suffer from the disadvantage that each bifocal image represents only about 40% of the available light and the remaining 20% of the light is lost in scatter.
What is still desired is a new and improved intraocular lens implant wherein the coaxial position of the central optic along the vision axis may be changed by control of the user and accommodate automatically. Preferably, the new and improved intraocular lens implant will utilize the ciliary muscle action and to effect accommodation movement of the lens optic along the vision axis of the eye between a distant vision position to a near vision position.
The inventors have realized that an intraocular implant device may provide accommodation. For example, an implant may include an optic portion, e.g. a lens, positioned along a vision axis of the eye. At least one centering anchor portion of the implant is received by the ciliary sulcus of the eye, and at least one fixation anchor portion is received by the ciliary body, ciliary muscle, or zonules. One or more haptics connect the centering and fixation anchor portions to the optic portion. The fixation anchor portions move in response to the natural action (i.e. contraction or relaxation) of the ciliary body/muscle. This motion is transferred by one or more haptics to the optic portion, moving it along the vision axis, and thereby providing accommodation. During this action, the centering anchor portions received by the sulcus remain substantially stationary, and operate, along with one or more haptics to maintain the alignment of the optic portion with the vision axis.
In one aspect, disclosed is an accommodating intraocular implant apparatus for implantation in the human eye, which includes: an optic portion having a periphery and an optic axis, the optic portion lying substantially within an optic plane transverse to the optic axis; at least one flexible haptic extending from a point on or near the periphery of the optic portion; at least one flexible haptic having a fixation anchor portion distal to the periphery of the optic portion; and at least one flexible haptic having a centering anchor portion. the fixation anchor portion and the centering anchor portion are adapted to couple to a portion of the eye.
In some embodiments, the optic axis is adapted for coaxial alignment with a vision axis of the eye. In some embodiments, at least one centering anchor portion is adapted to couple to the ciliary sulcus of the eye; at least one fixation anchor portion is adapted to couple to one of: a ciliary body, a ciliary muscle, or a ciliary zonule of the eye; at least one flexible haptic is adapted to connect the optic portion to the at least one centering anchor portion to maintain the coaxial alignment of the optic axis with the vision axis, and at least one haptic is configured to connect the optic portion to the at least one fixation anchor portion and, in response to ciliary muscle action in the eye, move the optic portion along the vision axis to provide accommodation.
In some embodiments, at least one flexible haptic includes at least one centering anchor portion and a least one fixation anchor portion. In some embodiments, the at least one flexible haptic includes a first connecting portion extending from the periphery of the optic portion to one of: the at least one fixation anchor portion and the at least one centering anchor point. The at least one flexible haptic may include a second connecting portion extending between the at least one fixation anchor portion and the at least one centering anchor portion. In some such embodiments, the periphery of the optic portion includes a circumferential edge which lies substantially in the optic plane, and the first connecting portion extends from the circumferential edge to the at least one fixation anchor portion at an angle to the optic plane. In some embodiments, the first connecting portion extends away from the optic plane on a side of the optic plane adapted to face towards the posterior of the eye. In some embodiments, the at least one centering anchor portion lies substantially within the optic plane.
In some embodiments, at least one flexible haptic includes a closed loop type haptic extending from the periphery of the optic portion, an open loop type haptic extending from the periphery of the optic portion, a straight type haptic extending from the periphery of the optic portion, or a includes a paddle type haptic extending from the periphery of the optic portion.
In some embodiments, at least one flexible haptic includes at least one fixation anchor portion, the anchor portion extending from a surface of the at least one flexible haptic adapted to face the anterior portion of the human eye.
In some embodiments, at least one haptic includes the at least one fixation anchor portion, the anchor portion extending from a surface of the at least one flexible haptic adapted to face the posterior portion of the human eye.
In some embodiments, the apparatus includes M centering anchoring portions, where M is a positive integer, and N fixation anchor portions, where N is a positive integer. For example, in some embodiments, M is greater than 1 and N is greater than 1.
In some embodiments, N is greater than 3. In some embodiments, N is greater than 7.
Some embodiments include multiple flexible haptics, each of the multiple flexible haptics configured to connect at least one centering anchor portion or at least one fixation anchor portion to the periphery of the optic portion.
In some embodiments, at least one flexible haptic is integral with the optic portion.
In some embodiments, the intraocular implant is foldable.
In some embodiments, the implant includes a material selected from the group consisting of: hydrogel, collagen, collamar, collagel, acrylate polymers, methacrylate polymers, silicone polymers, and composites thereof.
Some embodiments include a first flexible haptic and a second flexible haptic, each of the haptics including: a first connecting portion extending between the periphery of the optic portion and a first fixation anchor portion, a second connecting portion extending between the first fixation anchor portion and a centering anchor portion, a third connecting portion extending between the centering anchor portion and a second fixation anchor point; a fourth connecting portion extending between the second fixation anchor portion and the periphery of the optic portion. In some embodiments, the periphery of the optic portion includes a circumferential edge which lies substantially in the optic plane, and the first and fourth connecting portions extend from the circumferential edge to at an angle to the optic plane. In some embodiments, the first and fourth connecting portion extend away from the optic plane on a side of the optic plane adapted to face towards the posterior of the eye when the intraocular implant is implanted.
In some embodiments, the at least one fixation anchor portion includes one of: a serrated portion, a wedge shaped portion, a cylindrical portion, multiple connected wedge shaped portions, multiple connected cylindrical portions, a bar shaped portion.
In another aspect, a method for correcting vision in a human eye is disclosed including implanting an accommodating intraocular implant in the eye. The intraocular implant being of any of the types described above. In some embodiments, the implanting includes: coupling at least one centering anchor portion to the ciliary sulcus of the eye; coupling at least one fixation anchor portion to one of: a ciliary body, a ciliary muscle, a ciliary zonule of the eye.
In some embodiments, the implanting further includes: making an incision in the eye; folding the accommodating intraocular implant into a folded state small enough to pass through the incision; passing the accommodating intraocular implant through the incision to a desired position within the eye; and unfolding the accommodating intraocular implant to an unfolded state suitable for coupling to the eye. Some embodiments further include removing the natural crystalline lens of the eye.
Embodiments may include any of the above described features alone or in combination.
a is a side view of implant 10 positioned within an aphakic human eye;
b is a side view of implant 10 positioned within an aphakic human eye showing accommodation in response to ciliary muscle relaxation;
a shows a front view of implant 10;
b shows a cross section of implant 10;
c shows a front view of implant 10;
d shows a cross section of implant 10;
e shows a front view of implant 10;
f shows a cross section of implant 10;
g shows a front view of implant 10;
h shows a cross section of implant 10;
i shows a front view of implant 10;
j shows a cross section of implant 10;
a shows a front view of implant 10;
b shows a side elevation of implant 10;
a shows a front view of implant 10 with an exemplary haptic configuration.
b shows a front view of implant 10 with an exemplary haptic configuration similar to that given in
a shows a front view of implant 10 with an exemplary haptic configuration.
b shows a front view of implant 10 with an exemplary haptic configuration similar to that given in
a shows a front view of implant 10 with an exemplary haptic configuration.
b shows a front view of implant 10 with an exemplary haptic configuration similar to that given in
a shows a front view of implant 10 with an exemplary haptic configuration.
b shows a front view of implant 10 with an exemplary haptic configuration similar to that given in
Like reference numerals and labels refer to like elements throughout the figures.
In the eye, the natural lens of the eye separates the aqueous humor from the vitreous body. The iris separates the region between the cornea or anterior of the eye and the lens into an anterior chamber and a posterior chamber. The natural crystalline lens is contained in a membrane known as the capsule or capsular bag. When the natural lens is removed from the eye, the capsule may also be removed (intracapsular excision), or the anterior portion of the capsule may be removed with the natural crystalline lens, leaving the posterior portion of the capsule intact (extracapsular extraction), often leaving small folds or flaps from the anterior portion of the capsule. In an intraocular implant, an artificial lens may be inserted in the anterior chamber, the posterior chamber, or the capsular sac.
j through show an exemplary embodiment of an accommodating intraocular implant 10 according to the present disclosure for implantation in the human eye. Throughout the figures, the orientation with respect to the eye is shown relative to vision axis A, which appears in side views as a dotted arrow pointing toward the anterior (front) portion of the eye. The axis A appears in front views as a black dot, indicating that the anterior facing point of the arrow would pierce through the page toward the reader in the front view. In each figure showing a front view, an orientation is assumed where the top of patient's head would be towards the top of the figure (“twelve o'clock”), while the patient's feet would be toward the bottom of the figure (“six o'clock”).
Referring to
a and 6b show a side view of implant 10 positioned within the posterior chamber 23 outside of capsular bag remnant 24 of aphakic human eye 26. Fixation anchor portions 16 extend from the sides of haptics 20 facing the anterior of the eye 26 and are received by the zonules 28 of the ciliary body/muscle 18. Centering anchor portions 14 are received by the ciliary sulcus 15.
In
During the muscle action and accommodation motion of optic portion 12, centering anchor portions 16 anchored in the sulcus remain substantially stationary. Haptics 20 connect the substantially fixed centering anchor portions to optic portion 12, and thereby act to maintain the coaxial alignment of optic portion 12 with vision axis A. Accordingly, accommodation is provided while maintaining good centration (e.g. coaxial alignment along vision axis A) of optic portion 12 of implant 10.
a, 7c, 7e, 7g, and 7i show front views of implant 10;
d shows a cross section of implant 10 intersecting haptics 20 at portions along the haptic loop midway between a fixation anchor portion 16 and a centering anchor portion 14. At this point the haptics 20 are posterior to optic portion 12, as fixation anchor portions 16 are posterior to and the accompanying centering anchor portions 14, which, as noted above, in the same plane as the optic portion 12.
f shows a cross section of implant 10 through the haptics 20 along the portions of the haptics 20 extending from edge 22 of optic portion 12 to fixation anchor portions 16. As noted above, these portions of the haptics 20 angle posterior to the optic portion 12. Fixation anchor portions 16 are formed as angled tips of the haptic.
h shows a cross section of implant 10 through a portion 32 of a first haptic 20 connecting a centering anchor portion 14 and a fixation anchor portion 16, and through a portion 34 of a second haptic 20 extending from edge 22 of optic portion to fixation anchor portion 16. Portion 32 of the first haptic 20 angles towards the anterior to connect to the centering anchor portion 14 located in the plane of the optic portion 12. Portion 34 of the second haptic 20 angles towards the posterior to connect to fixation anchor portion 16. Again, the fixation anchor portion 16 is shown formed as an angled tip of haptic 20.
j shows a cross section of implant 10 through the fixation anchor portions 16. Fixation anchor portions 16 are shown formed as angled tips of haptics 20, with a serrated surface on the posterior sides of the haptics 20 at the tips for gripping the zonules 28 of the ciliary body/muscle 18.
a shows a front view of implant 10;
Although on exemplary embodiment is shown above, it is to be understood that various modifications and alternative embodiments are within the scope of this disclosure. For example, as shown in
b show embodiments of implant 10 featuring various haptic configurations. For example,
a shows a front view of an embodiment of implant 10 featuring two centering anchor portions 14 received by the sulcus 15 and two fixation anchor portions 16 received by the ciliary body 18. The centering anchor portions 14 are connected to optic portion 12 with open loop type haptics 30 extending in opposing directions from the circumferential edge 22 of optic portion 12. Similarly, the fixation anchor portions 16 are connected to optic portion 12 with open loop type haptics 30, each open loped haptic 30 extending in from the circumferential edge 22 in substantially the same direction as a corresponding closed loop haptic 20.
b shows a front view of an embodiment of implant 10 similar to that shown in
a shows a front view of an embodiment of implant 10 featuring two centering anchor portions 14 received by the sulcus 15 and four fixation anchor portions 16 received by the ciliary body 18. Each of two closed loop type haptics 20 extend from circumferential edge 22 to the ciliary body 18 and connect a pair of the fixation anchor portions 16 to optic portion 12. The centering anchor portions 14 are connected to optic portion 12 by open loop type haptics 30 extending from circumferential edge 22 to the sulcus 15. As shown in
a shows a front view of an embodiment of implant 10 featuring two centering anchor portions 14 received by the sulcus 15 and eight fixation anchor portions 16 received by the ciliary body 18. Each fixation anchor portions 16 is connected to optic portion 12 by a closed loop type haptic 20 extending from circumferential edge 22 to ciliary body 16. The centering anchor portions 14 are connected to optic portion 12 by open loop type haptics 30 extending from circumferential edge 22 to the sulcus 15.
Although several examples of haptic systems are presented above, it is to be understood that other suitable configurations may be used. Any number of haptics may be used. Each haptic may connect optic portion 12 to one or more of the centering anchor portions 14 or the fixation anchor portions 16. The connected anchor portions may be integral with the haptic. As shown above, the haptics may be of the open loop type, closed loop type, or straight type. In some embodiments the haptic may be of the paddle type, i.e. solid element (without a central aperture) bounded by a curved, e.g., C-shaped or U-shaped, peripheral edge. The haptics may extend from one or more positions on the periphery of optic portion 12.
Referring to
Optic portion 12 may be ground to the required diopter measurements necessary for vision correction. Optic portion 12 may form a lens, and the lens may be a negative or positive meniscus lens and may include correction for astigmatism. Depending on the refractive index of the material used, and the required vision correction, optic portion 2 may have the same thickness at central portion 87 and circumferential edge 22, or central portion 87 may be thinner than circumferential edge 22. In one embodiment, the thickness of optic 12 is 1 mm.
In some embodiments, implant 10 is designed to be foldable to facilitate insertion through small incisions, e.g., 3 mm in length or less. The device can be folded in the optic body, at any point in the flexible haptics, at the junction points between the optic body and the flexible haptics, or all of the above. The device can be folded with single or multiple folds along any direction.
Implant 10 can be usefully implanted into the eye as either a refractive phakic intraocular lens assembly or an aphakic intraocular lens assembly. Phakic intraocular lens implantation is becoming more popular because of their good refractive and visual results and because they are relatively easy to implant in most cases (Zaldivar & Rocha, 36 Int. Ophthalmol. Clin. 107-111 (1996); Neuhann et al., 14 J. Refract. Surg. 272-279 (1998); Rosen & Gore, 24 J. Cataract Refract. Surg. 596-606 (1998); Sanders et al., 24 J. Cataract Refract. Surg. 607-611 (1998)). The implantation can be performed by an ordinarily skilled ophthalmologist. Little surgical injury occurs to the ocular tissues during such implantation. When the surgical quality is not compromised, the results are highly predictable, immediate, and lasting.
For typical applications, suitable materials for implant 10 are solid, flexible, foldable optical, non-biodegradable materials such as hydrogel, collamer, collagel (hydrogel-collagen blends) acrylic polymers, polymethylmethacrylate (PMMA) and silicone polymers. The implant 10 may also be made of a composite of materials, i.e. where the flexible haptics are fabricated from one material and optic portion 12 from another material, for example, acrylic optics and hydrogel haptics. Where the lens assembly is used in the aphakic eye, flexible, but less foldable, materials may be preferred. For example, for the aphakic eye, the implant 10 may be made of all PMMA or a composite of PMMA optics and prolene haptics.
The implantation of implant 10 can generally be performed as provided by (Singh, eMedicine Ophthalmology (2000) http://www.emedicine.com/oph/topic662.htm).
First, the administration of local antibiotic drops is begun. A useful antibiotic is Tobramycin 0.3%, 1 drop, 6 times a day. Then, the pupil of the eye is contracted with 1% pilocarpine drops, administered for example at 15-minute intervals, starting 45 minutes before surgery. Drops (such as NSAID drops) are administered 2 times before surgery to minimize inflammation.
General anesthesia can be performed on the patient, but local anesthesia is preferred. For local anesthesia, 2% lidocaine with 7.5 U/ml hyaluronidase can be given 10 minutes before surgery. Orbital compression is applied to make the eye soft and to reduce orbital pressure.
For preparation of the surgical field, the periorbital skin of the patient is painted with iodine, then 5% povidine is applied. 5% povidine is also applied two-three times to the lid margin and the conjunctival fomices. Then, the eye is washed with saline.
An eye speculum is used for exposure of the surgical field. Upper and lower lid sutures, as well as superior rectus sutures can be applied in place of the speculum. (A sutureless procedure can also be used.) Adhesive plastic, applied to the surface of the eyelids, is used to pull the eyelashes.
For making small intraoperative incisions, a side port (for example, 0.6 mm) is made in the anterior chamber. This injection is started at the opposite limbus. As the aqueous fluid drains, it is replaced, for example, with a viscoelastic agent. The depth of the anterior chamber is not reduced at any time.
In one embodiment, for implantation of the implant 10 into the eye, two side ports are made to introduce the instruments that are used to fix the iris to the haptics. The width of the incision depends on the diameter of the intraocular lens assembly of the invention (being, for example, 4-5 mm). The incision may be made at the limbus or in the clear cornea. If a pocket section is made, wound closure (see, below) can be made without sutures. The intraocular lens assembly of the invention can then be introduced in the pre-crystalline space with angled-suture forceps the lens is positioned, for example, behind the iris on a horizontal axis with a cyclodialysis spatula. The intraocular lens assembly of the invention is then manipulated to center the optic on the pupil. During implantation of implant into the anterior chamber, the lens is centered and fixed so that it does not slip out of position. The lens can be positioned between the cornea and the iris, but avoiding contact with either to prevent corneal damage, proliferation of corneal epithelium on the anterior surface of the lens causing opacification, or iris. If the lens is not positioned properly with respect to the pupil, too much light may be admitted to the retina, causing serious vision difficulties. The haptics generally lodge as described above. Also, the anterior chamber of the eye is filled with the aqueous humor, a fluid secreted by the ciliary process, passing from the posterior chamber to the anterior chamber through the pupil, and from the angle of the anterior chamber it passes into the spaces of Fontana to the pectinate villi through which it is filtered into the venous canal of Schlemm. The implanted lens is positioned so the flow of fluid is not blocked.
After implant 10 is implanted, the viscoelastic material (if previously introduced into the eye chambers) is removed from the anterior and posterior chambers of the eye with an aspiration syringe (such as a 24-gauge cannula). Implant 10 is fixed and centered by the haptics of the lens as described in the examples above. The anterior chamber is washed thoroughly with saline. The pupil is contracted with intraocular acetylcholine 1%, carbachol 0.01%, or pilocaipine 0.5% solution. The incision is closed by hydrating the corneal incisions. A suture rarely is needed.
In another embodiment, for implantation of implant 10, the main incision is made at the ventral area of the eye (at the “top” of the eye, at “12 o'clock”). The width is preferably equal to the size of the optic, which may be 4-5 mm. Side incisions are made, approximately 1 mm wide. Implant 10 is inserted then vertically. Implant 10 rotated inside the viscoelastic-filled anterior chamber; the haptics are placed horizontally as in the examples provided above.
In some embodiments, fixating implant 10 may be a bimanual procedure. Implant 10 may be implanted using special tools to compress the haptics, such as forceps or cannulae, or may rely on microhooks to manipulate the optic through a hole in the surface of the optic (see discussion in U.S. Pat. No. 6,142,999). A vertically-holding lens forceps, which enters the anterior chamber through the main incision, centers the optic on the pupil and holds it steadily. A thin forceps is introduced from the side incision and grasps the iris close to the claw, allowing manipulation of the iris, and/or fixation of one or more of the haptics, for example, in the configurations described above. Both instruments are withdrawn, and the surgeon changes hands for holding each tool. The anterior chamber of the eye is again deepened with viscoelastic material, and the lens-fixation instruments are reintroduced. A second haptic-fixation maneuver may then be performed through the incision on the opposite side. Accordingly, implant 10 may be centered and fixated using the techniques described above, providing accommodation for the patient.
A peripheral iridectomy can then be performed. Then, the introduced viscoelastic material (if any) is aspirated through the three incisions. The anterior chamber is gently irrigated and inflated with air to remove all viscoelastic material.
For closure of the incision line, the apposition of the sides of the incision may be achieved by one or two superficial sutures. Alternatively, a large air bubble may be left inside the anterior chamber to effect an apposition. If the limbal incision was made without a pocket, then a closure of the incision line should be performed using sutures.
At the end of the surgery, 20 mg of gentamycin and 2 mg of dexamethasone are subconjunctivally injected. A sterile pad and a protective shield are applied.
In some embodiments, the intraocular lens assembly of the invention can be located in the posterior chamber of the eye, using methods known to those of skill in the ophthalmic art.
Aphakic implantation is also usefully provided for by implant 10. As noted above, the lens assembly can be surgically implanted outside or inside of the evacuated capsular bag of the lens of an eye. When implanted inside the capsular bag (for example, through the anterior capsule opening in the bag), implant 10 may be placed in a position such that optic portion 12 is aligned with the opening defined by the anterior capsular remnant. Implant 10 may be centered and fixated using the techniques described above, providing accommodation for the patient.
Advantageously, in some embodiments post-operative atropinization of the optic ciliary muscle is not required for implant 10 (when implanted either as a refractive phakic intraocular lens or an aphakic intraocular lens) to achieve accommodation. During surgery, especially for implantation of aphakic intraocular lenses, the ciliary muscle of the eye had previously and typically been paralyzed with a ciliary muscle relaxant to place the muscle in its relaxed state. Ciliary muscle relaxants include anticholinergics such as atropine, scopolamine, homatropine, cyclopentolate and tropicamide. Atropine is preferred. Proprietary preparations of atropine include Isopto Atropine (eye drops); Minims Atropine Sulphate (single-dose eye drops); Min-I-Jet Atropine (injection); Actonorm Powder (combined with antacids and peppermint oil); Atropine-1; Atropine-Care; Atropisol; Isopto Atropine; Ocu-tropine; Atropair; Atropine Sulfate S.O.P.; Atrosulf; 1-Tropine; Isopto Atropine; and Ocu-Tropine. Prior to this invention (i.e., while implanting intraocular lenses not having the advantages of the foldable intraocular lens assembly of the invention), the patient's eye would be atropinized following surgery, to allow for accommodation of the lens of the implanted aphakic intraocular lens assembly to the eye (see discussion, U.S. Pat. No. 6,051,024). Following surgery, the ciliary muscle relaxant (such as atropine) would be periodically introduced throughout a post-operative fibrosis and healing period (such as two to three weeks) to maintain the ciliary muscle in its relaxed state until fibrosis was complete. This drug-induced relaxation of the ciliary muscle prevented contraction of the ciliary muscle and immobilized the capsular bag. Thus, the implanted intraocular lens optic fixed during fibrosis in its distant vision position within the eye relative to the retina (accommodation). The implanted lens pressed backward against and thereby forwardly stretched the elastic posterior capsule of the capsular bag. By contrast, because of the haptic design of the intraocular lens assembly of the invention, the lens can, when fixated and centered using the techniques described above, provide accommodation for the patient without the administration of post-operative atropine.
It will be apparent to those skilled in the art that other changes and modifications can be made in the above-described invention and methods for making and using the same, without departing from the scope of the invention herein, and it is intended that all matter contained in the above description shall be interpreted in an illustrative and not in a limiting sense.
Number | Name | Date | Kind |
---|---|---|---|
3673616 | Fedorov et al. | Jul 1972 | A |
3866249 | Flom | Feb 1975 | A |
3906551 | Otter | Sep 1975 | A |
3913148 | Potthast | Oct 1975 | A |
3975779 | Richards et al. | Aug 1976 | A |
4014049 | Richards et al. | Mar 1977 | A |
4053953 | Flom et al. | Oct 1977 | A |
4073014 | Poler | Feb 1978 | A |
4087866 | Choyce et al. | May 1978 | A |
4092743 | Kelman | Jun 1978 | A |
4102567 | Cuffe et al. | Jul 1978 | A |
4136406 | Norris | Jan 1979 | A |
4141973 | Balazs | Feb 1979 | A |
4159546 | Shearing | Jul 1979 | A |
4173281 | Trought | Nov 1979 | A |
4174543 | Kelman | Nov 1979 | A |
4190049 | Hager et al. | Feb 1980 | A |
4198980 | Clark | Apr 1980 | A |
4215440 | Worst | Aug 1980 | A |
4240163 | Galin | Dec 1980 | A |
4242760 | Rainin | Jan 1981 | A |
4244060 | Hoffer | Jan 1981 | A |
4249271 | Poler | Feb 1981 | A |
4251887 | Anis | Feb 1981 | A |
4254509 | Tennant | Mar 1981 | A |
4254510 | Tennant | Mar 1981 | A |
4269307 | LaHaye | May 1981 | A |
4270230 | Poler | Jun 1981 | A |
4280232 | Hummel | Jul 1981 | A |
4285072 | Morcher et al. | Aug 1981 | A |
4325375 | Nevyas | Apr 1982 | A |
4326306 | Poler | Apr 1982 | A |
4349027 | DiFrancesco | Sep 1982 | A |
4363142 | Meyer | Dec 1982 | A |
4363143 | Callahan | Dec 1982 | A |
4366582 | Faulkner | Jan 1983 | A |
4370760 | Kelman | Feb 1983 | A |
4409691 | Levy | Oct 1983 | A |
4423809 | Mazzocco | Jan 1984 | A |
4435855 | Pannu | Mar 1984 | A |
4441217 | Cozean, Jr. | Apr 1984 | A |
4446581 | Blake | May 1984 | A |
4451938 | Kelman | Jun 1984 | A |
4463458 | Seidner | Aug 1984 | A |
4468820 | Uhler et al. | Sep 1984 | A |
4480340 | Shepard | Nov 1984 | A |
4494254 | Lopez | Jan 1985 | A |
4504981 | Walman | Mar 1985 | A |
4508216 | Kelman | Apr 1985 | A |
4517295 | Bracke et al. | May 1985 | A |
4527294 | Heslin | Jul 1985 | A |
4530117 | Kelman | Jul 1985 | A |
4534069 | Kelman | Aug 1985 | A |
4536895 | Bittner | Aug 1985 | A |
4573998 | Mazzocco | Mar 1986 | A |
4575374 | Anis | Mar 1986 | A |
4576607 | Kelman | Mar 1986 | A |
4581033 | Callahan | Apr 1986 | A |
4585456 | Blackmore | Apr 1986 | A |
4591358 | Kelman | May 1986 | A |
4608049 | Kelman | Aug 1986 | A |
4615703 | Callahan et al. | Oct 1986 | A |
4619256 | Horn | Oct 1986 | A |
4624669 | Grendahl | Nov 1986 | A |
4629460 | Dyer | Dec 1986 | A |
4634423 | Bailey, Jr. | Jan 1987 | A |
4638056 | Callahan et al. | Jan 1987 | A |
4655775 | Clasby, III | Apr 1987 | A |
4676792 | Praeger | Jun 1987 | A |
4676794 | Kelman | Jun 1987 | A |
4684014 | Davenport | Aug 1987 | A |
4687484 | Kaplan | Aug 1987 | A |
4700638 | Przewalski | Oct 1987 | A |
4701181 | Arnott | Oct 1987 | A |
4704123 | Smith | Nov 1987 | A |
4710195 | Giovinazzo | Dec 1987 | A |
4711638 | Lindstrom | Dec 1987 | A |
4718906 | Mackool | Jan 1988 | A |
4736836 | Alongi et al. | Apr 1988 | A |
4764169 | Grendahl | Aug 1988 | A |
4769035 | Kelman | Sep 1988 | A |
4778464 | Sergienko et al. | Oct 1988 | A |
4781719 | Kelman | Nov 1988 | A |
4787902 | Sheets et al. | Nov 1988 | A |
4795460 | Anis | Jan 1989 | A |
4795462 | Grendahl | Jan 1989 | A |
4804361 | Anis | Feb 1989 | A |
4816032 | Hetland | Mar 1989 | A |
4828558 | Kelman | May 1989 | A |
4834750 | Gupta | May 1989 | A |
4842600 | Feaster | Jun 1989 | A |
RE33039 | Arnott | Aug 1989 | E |
4852566 | Callahan et al. | Aug 1989 | A |
4863462 | Fedorov et al. | Sep 1989 | A |
4863463 | Tjan | Sep 1989 | A |
4863465 | Kelman | Sep 1989 | A |
4871363 | Kelman | Oct 1989 | A |
4872876 | Smith | Oct 1989 | A |
4878911 | Anis | Nov 1989 | A |
4888012 | Horn | Dec 1989 | A |
4919130 | Stoy et al. | Apr 1990 | A |
4923296 | Erickson | May 1990 | A |
4932970 | Portney | Jun 1990 | A |
4950290 | Kamerling | Aug 1990 | A |
4994080 | Shepard | Feb 1991 | A |
4995714 | Cohen | Feb 1991 | A |
5002568 | Katzen | Mar 1991 | A |
5019098 | Mercier | May 1991 | A |
5047052 | Dubroff | Sep 1991 | A |
5076684 | Simpson et al. | Dec 1991 | A |
5098444 | Feaster | Mar 1992 | A |
5100226 | Freeman | Mar 1992 | A |
5108429 | Wiley | Apr 1992 | A |
5118452 | Lindsey et al. | Jun 1992 | A |
5123905 | Kelman | Jun 1992 | A |
5133747 | Feaster | Jul 1992 | A |
5133749 | Nordan | Jul 1992 | A |
5166711 | Portney | Nov 1992 | A |
5171320 | Nishi | Dec 1992 | A |
5176686 | Poley | Jan 1993 | A |
5178636 | Silberman | Jan 1993 | A |
5192319 | Worst | Mar 1993 | A |
5197981 | Southard | Mar 1993 | A |
5199559 | Dark | Apr 1993 | A |
5229797 | Futhey et al. | Jul 1993 | A |
5236452 | Nordan | Aug 1993 | A |
5258025 | Fedorov et al. | Nov 1993 | A |
5266074 | Nishi et al. | Nov 1993 | A |
5281227 | Sussman | Jan 1994 | A |
5361780 | Kellan | Nov 1994 | A |
5366501 | Langerman | Nov 1994 | A |
5370652 | Kellan | Dec 1994 | A |
5405386 | Rheinish et al. | Apr 1995 | A |
5425734 | Blake | Jun 1995 | A |
D360068 | Hambleton et al. | Jul 1995 | S |
5443506 | Garabet | Aug 1995 | A |
5468246 | Blake | Nov 1995 | A |
5476512 | Sarfarazi | Dec 1995 | A |
5476514 | Cumming | Dec 1995 | A |
5480428 | Fedorov et al. | Jan 1996 | A |
5489302 | Skottun | Feb 1996 | A |
5496366 | Cumming | Mar 1996 | A |
5507806 | Blake | Apr 1996 | A |
5522890 | Nakajima et al. | Jun 1996 | A |
5549670 | Young et al. | Aug 1996 | A |
5593436 | Langerman | Jan 1997 | A |
5628794 | Lindstrom | May 1997 | A |
5643275 | Blake | Jul 1997 | A |
D382399 | Hambleton et al. | Aug 1997 | S |
5674282 | Cumming | Oct 1997 | A |
5682223 | Menezes et al. | Oct 1997 | A |
5697973 | Peyman | Dec 1997 | A |
5709220 | Kellan | Jan 1998 | A |
5713958 | Weiser | Feb 1998 | A |
5772667 | Blake | Jun 1998 | A |
5782911 | Herrick | Jul 1998 | A |
5800532 | Lieberman | Sep 1998 | A |
5847802 | Menezes et al. | Dec 1998 | A |
5855605 | Herrick | Jan 1999 | A |
5919229 | Portney | Jul 1999 | A |
5928282 | Nigam | Jul 1999 | A |
5947976 | Van Noy et al. | Sep 1999 | A |
5976150 | Copeland | Nov 1999 | A |
6010510 | Brown | Jan 2000 | A |
6013101 | Israel | Jan 2000 | A |
6015435 | Valunin | Jan 2000 | A |
6051024 | Cumming | Apr 2000 | A |
6083261 | Callahan et al. | Jul 2000 | A |
6090141 | Lindstrom | Jul 2000 | A |
6096077 | Callahan et al. | Aug 2000 | A |
6110202 | Barraquer et al. | Aug 2000 | A |
6120148 | Fiala et al. | Sep 2000 | A |
6129723 | Anderson | Oct 2000 | A |
6142999 | Brady et al. | Nov 2000 | A |
6152958 | Nordan | Nov 2000 | A |
6197059 | Cumming | Mar 2001 | B1 |
6203549 | Waldock | Mar 2001 | B1 |
6224628 | Callahan et al. | May 2001 | B1 |
6241777 | Kellan | Jun 2001 | B1 |
6261321 | Kellan | Jul 2001 | B1 |
6277146 | Peyman et al. | Aug 2001 | B1 |
6299641 | Woods | Oct 2001 | B1 |
6398786 | Sesic | Jun 2002 | B1 |
6443985 | Woods | Sep 2002 | B1 |
6447519 | Brady | Sep 2002 | B1 |
6461384 | Hoffmann | Oct 2002 | B1 |
6488707 | Callahan et al. | Dec 2002 | B1 |
6488709 | Barrett | Dec 2002 | B1 |
6494911 | Cumming | Dec 2002 | B2 |
6517577 | Callahan et al. | Feb 2003 | B1 |
6533813 | Lin et al. | Mar 2003 | B1 |
6537283 | Van Noy | Mar 2003 | B2 |
6605093 | Blake | Aug 2003 | B1 |
6622855 | Callahan et al. | Sep 2003 | B1 |
6623522 | Nigam | Sep 2003 | B2 |
6645246 | Weinschenk, III | Nov 2003 | B1 |
6666887 | Callahan et al. | Dec 2003 | B1 |
6749633 | Lorenzo | Jun 2004 | B1 |
6786928 | Callahan et al. | Sep 2004 | B2 |
6797004 | Brady | Sep 2004 | B1 |
6800091 | Callahan et al. | Oct 2004 | B2 |
6921415 | Callahan et al. | Jul 2005 | B2 |
6976989 | Vincent | Dec 2005 | B1 |
7037328 | Vincent | May 2006 | B2 |
7037338 | Nagamoto | May 2006 | B2 |
7063723 | Ran | Jun 2006 | B2 |
7125422 | Woods | Oct 2006 | B2 |
7179292 | Worst | Feb 2007 | B2 |
7220279 | Nun | May 2007 | B2 |
7223288 | Zhang | May 2007 | B2 |
7279006 | Vincent | Oct 2007 | B2 |
7354451 | Koch | Apr 2008 | B2 |
7503938 | Phillips | Mar 2009 | B2 |
7713299 | Brady et al. | May 2010 | B2 |
8043372 | Bumbalough | Oct 2011 | B2 |
20010001836 | Cumming | May 2001 | A1 |
20010012964 | Lang | Aug 2001 | A1 |
20010044657 | Kellan | Nov 2001 | A1 |
20020055777 | Cumming et al. | May 2002 | A1 |
20020072673 | Yamamoto | Jun 2002 | A1 |
20020095212 | Boehm | Jul 2002 | A1 |
20020103536 | Landreville et al. | Aug 2002 | A1 |
20020120331 | Galin et al. | Aug 2002 | A1 |
20020161437 | Zhou et al. | Oct 2002 | A1 |
20020193877 | Hoffmann et al. | Dec 2002 | A1 |
20030033013 | Callahan | Feb 2003 | A1 |
20030050695 | Lin et al. | Mar 2003 | A1 |
20030065387 | Callahan et al. | Apr 2003 | A1 |
20030078655 | Callahan | Apr 2003 | A1 |
20030114927 | Nagamoto | Jun 2003 | A1 |
20030130732 | Sarfarazi | Jul 2003 | A1 |
20030135273 | Callahan | Jul 2003 | A1 |
20030149480 | Shadduck et al. | Aug 2003 | A1 |
20040215340 | Messner | Oct 2004 | A1 |
20040230300 | Bandhauer et al. | Nov 2004 | A1 |
20040236423 | Zhang et al. | Nov 2004 | A1 |
20040249456 | Cumming | Dec 2004 | A1 |
20050033308 | Callahan | Feb 2005 | A1 |
20050107875 | Cumming | May 2005 | A1 |
20050251253 | Gross | Nov 2005 | A1 |
20060047339 | Brown | Mar 2006 | A1 |
20060047340 | Brown | Mar 2006 | A1 |
20060100704 | Blake | May 2006 | A1 |
20060142781 | Pynson et al. | Jun 2006 | A1 |
20060235515 | Chassain | Oct 2006 | A1 |
20060247767 | Koch | Nov 2006 | A1 |
20060293694 | Futamura | Dec 2006 | A1 |
20070093892 | Mackool | Apr 2007 | A1 |
20070239274 | Kellan | Oct 2007 | A1 |
20080161913 | Brady et al. | Jul 2008 | A1 |
20080281417 | Nagamoto | Nov 2008 | A1 |
20090171458 | Kellan et al. | Jul 2009 | A1 |
20090248031 | Ichinohe et al. | Oct 2009 | A1 |
20100131059 | Callahan et al. | May 2010 | A1 |
20100131061 | Callahan et al. | May 2010 | A1 |
20100179652 | Yamamoto | Jul 2010 | A1 |
20100228260 | Callahan et al. | Sep 2010 | A1 |
20110191086 | Callahan | Aug 2011 | A1 |
20110313522 | Hayes | Dec 2011 | A1 |
20110313523 | Hayes | Dec 2011 | A1 |
Number | Date | Country |
---|---|---|
1713862 | Dec 2005 | CN |
2556665 | Jun 1977 | DE |
2717706 | Oct 1978 | DE |
3722910 | Jan 1989 | DE |
4030005 | Mar 1992 | DE |
4040005 | Jun 1992 | DE |
1961399 | Apr 1991 | EP |
2653325 | Apr 1991 | FR |
2666503 | Mar 1992 | FR |
2687304 | Aug 1993 | FR |
2029235 | Mar 1980 | GB |
2124500 | Feb 1984 | GB |
2165456 | Apr 1986 | GB |
2000-245755 | Sep 2000 | JP |
1377086 | Feb 1988 | SU |
WO9817205 | Apr 1998 | WO |
WO9929266 | Jun 1999 | WO |
WO0078252 | Dec 2000 | WO |
WO03017867 | Jun 2003 | WO |
WO 2007117476 | Oct 2007 | WO |
WO2007117476 | Oct 2007 | WO |
WO 2007134019 | Nov 2007 | WO |
WO2007134019 | Nov 2007 | WO |
Entry |
---|
Zaldivar et al.; “The Current Status of Phakic Intraocular Lenses;” International Opthalmology Clinics; vol. 36, No. 4; 1996; pp. 107-111. |
Neuhann; “Corneal or Lens Refractive Surgery?” Journal of Refractive Surgery; vol. 14; May/Jun. 1998; pp. 272-279. |
Rosen et al.; “Staar Collamer Posterior Chamber Phakic Intraocular Lens to Correct Myopia and Hyperopia;” J. Cataract Refract. Surg.; vol. 24; May 1998; pp. 596-606. |
Sanders et al.; “Implantable Contact Lens for Moderate to High Myopia: Phase | FDA Clinical Study with 6 Month Follow-Up;” J. Cataract Refract. Surg.; vol. 24; May 1998; pp. 607-6111. |
Japan Office Action for Japanese Application 2009-504268, dated Apr. 24, 2012. |
Chinese Decision of Rejection for Chinese Application 200780020967.4, dated May 28, 2012. |
Chinese Office Action for Chinese Application 200780020967.4 dated Apr. 12, 2011. |
Austria Examination Report for Austrian Application 200807369-4 dated Mar. 10, 2010. |
PCT Search Report for PCT/US2009/065955 dated Jan. 27, 2010. |
PCT Patentability Report for PCT/US2009/065955 dated Jan. 27, 2010. |
PCT Search Report for PCT/US2009/065960 dated Jan. 27, 2010. |
PCT Patentability Report for PCT/US2009/065960 dated Jan. 27, 2010. |
PCT Search Report for PCT/US2007/008328 dated Jun. 19, 2008. |
PCT Patentability Report for PCT/US2007/008328 dated Jun. 19, 2008. |
PCT Search Report for PCT/US2008/088430 dated Aug. 11, 2009. |
PCT Patentability Report for PCT/US2008/088430 dated Aug. 11, 2009. |
PCT Search Report for PCT/US2010/026230 dated May 19, 2010. |
PCT Patentabilty Report for PCT/US2010/026230 dated May 19, 2010. |
PCT Search Report for PCT/US2006/16221 dated May 10, 2007. |
PCT Patentability Report for PCT/US2006/16221 dated May 10, 2007. |
PCT Search Report for PCT/US2011/37583 dated Nov. 15, 2011. |
PCT Patentabilty Report for PCT/US2011/37583 dated Nov. 15, 2011. |
Austria Examination Report for Austrian Application 2009319753, dated Aug. 29, 2012. |
PCT Search Report and Patentability Report for PCT/US12/40732, dated Sep. 18, 2012. |
EPO Search Report for PCT/US2007/008328, dated Oct. 26, 2012. |
EPO Opinion for PCT/US2007/008328, dated Oct. 26, 2012. |
Number | Date | Country | |
---|---|---|---|
20090171458 A1 | Jul 2009 | US |